UA72750C2 - Azabicycloalcanes as ccr5 modulators and pharmaceutical composition - Google Patents

Azabicycloalcanes as ccr5 modulators and pharmaceutical composition Download PDF

Info

Publication number
UA72750C2
UA72750C2 UA2001064397A UA2001064397A UA72750C2 UA 72750 C2 UA72750 C2 UA 72750C2 UA 2001064397 A UA2001064397 A UA 2001064397A UA 2001064397 A UA2001064397 A UA 2001064397A UA 72750 C2 UA72750 C2 UA 72750C2
Authority
UA
Ukraine
Prior art keywords
formula
title compound
dichloromethane
alkyl
reduced pressure
Prior art date
Application number
UA2001064397A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9921375.3A external-priority patent/GB9921375D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UA72750C2 publication Critical patent/UA72750C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
UA2001064397A 1998-12-23 1999-12-23 Azabicycloalcanes as ccr5 modulators and pharmaceutical composition UA72750C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9921375.3A GB9921375D0 (en) 1999-09-10 1999-09-10 CCR5 Modulators
PCT/IB1999/002048 WO2000038680A1 (en) 1998-12-23 1999-12-23 Azabicycloalkanes as ccr5 modulators

Publications (1)

Publication Number Publication Date
UA72750C2 true UA72750C2 (en) 2005-04-15

Family

ID=26314899

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001064397A UA72750C2 (en) 1998-12-23 1999-12-23 Azabicycloalcanes as ccr5 modulators and pharmaceutical composition

Country Status (48)

Country Link
US (1) US6586430B1 (el)
EP (1) EP1140085B1 (el)
JP (1) JP3602795B2 (el)
KR (1) KR100425612B1 (el)
CN (1) CN1331591A (el)
AP (1) AP1697A (el)
AR (1) AR024233A1 (el)
AT (1) ATE505190T1 (el)
AU (1) AU763644B2 (el)
BG (1) BG65448B1 (el)
BR (1) BRPI9917007B8 (el)
CA (1) CA2350073C (el)
CO (1) CO5300387A1 (el)
CR (2) CR6392A (el)
CU (1) CU23344A3 (el)
CY (1) CY1111504T1 (el)
CZ (1) CZ300926B6 (el)
DE (1) DE69943352D1 (el)
DK (1) DK1140085T3 (el)
DZ (2) DZ2979A1 (el)
EA (1) EA004988B1 (el)
EE (1) EE05170B1 (el)
EG (1) EG24400A (el)
GC (1) GC0000117A (el)
GE (1) GEP20033131B (el)
HK (1) HK1039902A1 (el)
HR (2) HRP20010468B1 (el)
HU (1) HU228754B1 (el)
ID (1) ID28965A (el)
IL (2) IL143512A0 (el)
IS (1) IS5944A (el)
MA (1) MA26714A1 (el)
ME (1) ME00513B (el)
NO (1) NO330677B1 (el)
NZ (1) NZ511794A (el)
OA (1) OA11735A (el)
PA (1) PA8487201A1 (el)
PE (1) PE20001420A1 (el)
PL (1) PL201875B1 (el)
PT (1) PT1140085E (el)
RS (1) RS51701B (el)
SI (1) SI1140085T1 (el)
SK (1) SK287020B6 (el)
TN (1) TNSN99252A1 (el)
TR (1) TR200101793T2 (el)
TW (1) TW577888B (el)
UA (1) UA72750C2 (el)
WO (1) WO2000038680A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1118858A3 (en) * 2000-01-12 2003-07-09 Pfizer Limited Assay method
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
DK1526134T3 (da) * 2000-05-26 2008-11-17 Pfizer Triazolyltropanderivater som CCR5-modulatorer
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
TW200800167A (en) * 2002-03-15 2008-01-01 Novartis Ag Organic compounds
GEP20074210B (en) * 2002-04-08 2007-10-10 Pfizer Tropane derivatives as ccr5 modulators
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
ATE384724T1 (de) 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
JP2006511554A (ja) * 2002-12-13 2006-04-06 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのピペリジン誘導体
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
US20070112022A1 (en) * 2003-07-31 2007-05-17 Dearg Brown Piperidine derivatives as ccr5 receptor modulators
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
JP4874107B2 (ja) * 2003-10-03 2012-02-15 ファイザー・インク Ｈｉｖ及び炎症の治療のためのｃｃｒ５受容体拮抗活性を有するイミダゾピリジン置換トロパン誘導体
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CA2552087C (en) * 2004-01-30 2011-01-25 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
JP2007532626A (ja) * 2004-04-14 2007-11-15 ファイザー・インク Ｈｉｖ治療用硫黄連結イミダゾール化合物
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
RU2006146608A (ru) 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
EP1869034A1 (en) * 2005-04-08 2007-12-26 NeuroSearch A/S (+) - and (-) -8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicycl (3.2.1.)oct-2-ene
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
EA200870344A1 (ru) 2006-03-10 2009-04-28 Оно Фармасьютикал Ко., Лтд. Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080015834A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
US20080014572A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
CA2673566A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
CA2697051C (en) * 2007-08-31 2013-12-17 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2011011652A1 (en) 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
CN104169425A (zh) 2011-03-09 2014-11-26 理查德·G·佩斯泰尔 前列腺癌细胞系、遗传标志及其用途
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CA2873743C (en) * 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
PH30413A (en) 1992-03-26 1997-05-09 Boehringer Ingelheim Italia Crystalline forms of endo-2,3-dihydro-n-(8-methyl)-8-azabicyclo-(3,2,1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
SK1296A3 (en) * 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
CN1168719C (zh) * 1996-03-29 2004-09-29 辉瑞大药厂 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0920306A2 (en) * 1996-07-12 1999-06-09 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998004554A1 (fr) * 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2278309A1 (en) 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
WO1999009984A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
CN1331591A (zh) 2002-01-16
EE200100345A (et) 2002-12-16
BG65448B1 (bg) 2008-08-29
JP2002533393A (ja) 2002-10-08
NO20013183L (no) 2001-08-08
CU23344A3 (es) 2009-02-20
GEP20033131B (en) 2003-12-25
TW577888B (en) 2004-03-01
EG24400A (en) 2009-04-29
CR9879A (es) 2008-06-20
ME00513B (me) 2011-10-10
BG105721A (en) 2002-02-28
DE69943352D1 (de) 2011-05-26
DZ2979A1 (fr) 2005-01-30
JP3602795B2 (ja) 2004-12-15
WO2000038680A1 (en) 2000-07-06
PT1140085E (pt) 2011-06-16
BRPI9917007B8 (pt) 2021-05-25
BRPI9917007B1 (pt) 2016-07-26
RS51701B (sr) 2011-10-31
IL143512A (en) 2013-06-27
AP2001002186A0 (en) 2001-06-30
SK287020B6 (sk) 2009-09-07
NZ511794A (en) 2003-10-31
KR20010089701A (ko) 2001-10-08
PL349495A1 (en) 2002-07-29
AR024233A1 (es) 2002-09-25
IL143512A0 (en) 2002-04-21
EP1140085A1 (en) 2001-10-10
PA8487201A1 (es) 2002-02-21
BR9917007A (pt) 2001-10-30
EA004988B1 (ru) 2004-10-28
CO5300387A1 (es) 2003-07-31
CA2350073C (en) 2007-04-17
IS5944A (is) 2001-05-15
PE20001420A1 (es) 2000-12-18
HRP20120132A2 (hr) 2012-03-31
SI1140085T1 (sl) 2011-08-31
KR100425612B1 (ko) 2004-04-01
CA2350073A1 (en) 2000-07-06
NO330677B1 (no) 2011-06-06
TNSN99252A1 (fr) 2005-11-10
NO20013183D0 (no) 2001-06-25
HUP0104795A3 (en) 2002-05-28
YU38801A (sh) 2005-06-10
PL201875B1 (pl) 2009-05-29
CZ300926B6 (cs) 2009-09-09
ATE505190T1 (de) 2011-04-15
HRP20010468B1 (en) 2012-06-30
AU763644B2 (en) 2003-07-31
HRP20120132B1 (hr) 2018-01-26
CY1111504T1 (el) 2015-08-05
DK1140085T3 (da) 2011-06-27
ID28965A (id) 2001-07-19
DZ3326A1 (fr) 2005-05-29
AU1675100A (en) 2000-07-31
EA200100589A1 (ru) 2002-02-28
HU228754B1 (en) 2013-05-28
HUP0104795A2 (hu) 2002-04-29
US6586430B1 (en) 2003-07-01
EE05170B1 (et) 2009-06-15
GC0000117A (en) 2005-06-29
SK8752001A3 (en) 2003-02-04
CR6392A (es) 2006-08-09
AP1697A (en) 2006-12-22
TR200101793T2 (tr) 2001-12-21
EP1140085B1 (en) 2011-04-13
HK1039902A1 (zh) 2002-05-17
HRP20010468A2 (en) 2003-02-28
HRP20120132A8 (hr) 2017-11-03
OA11735A (en) 2005-05-12
MA26714A1 (fr) 2004-12-20
CZ20012298A3 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
UA72750C2 (en) Azabicycloalcanes as ccr5 modulators and pharmaceutical composition
TWI736566B (zh) Ｔｌｒ７/８拮抗劑及其用途
RU2758686C2 (ru) Антагонисты tlr7/8 и их применение
TWI746178B (zh) 製備作為jak激酶抑制劑之萘啶化合物之方法
JP7098716B2 (ja) Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
JP6881879B2 (ja) Ｊａｋキナーゼ阻害剤としてのピリミジン化合物
CA3039912A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10548910B2 (en) Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
UA123010C2 (uk) Модулятори сот та способи їх застосування
AU1290400A (en) Piperidines as ccr5 modulators
UA71951C2 (en) Pyrimidines as sorbitol dehydrogenase inhibitors, a pharmaceutical composition containing them, intermediate compounds and a method for the preparation of intermediate compound
EP1013276A1 (en) Aminoazacycloalkanes as CCR5 modulators
WO2008134035A1 (en) Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives
IL144512A (en) A spontaneously dispersed medicinal preparation, a capsule containing it and its use in the preparation of drugs for the treatment of cancer
TW201932473A (zh) 巨環吲哚衍生物
ES2362711T3 (es) Azabicicloalcanos como moduladores de ccr5.
MXPA01006523A (en) Azabicycloalkanes as ccr5 modulators
TW201910325A (zh) 吲哚衍生物及其用途